Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
| Status: | Terminated |
|---|---|
| Conditions: | Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/27/2017 |
| Start Date: | February 25, 2013 |
| End Date: | June 23, 2016 |
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
This is the first study where BAY1000394 is given in combination with chemotherapy:
cisplatin / etoposide or carboplatin / etoposide. Patients with small cell lung cancer will
be treated. Every patient will receive drug treatment, there is no placebo group. Different
groups of patients will receive different dosages of BAY1000394 to determine the safety and
maximum tolerated dose (MTD) of BAY1000394 in combination with chemotherapy. The dose of
chemotherapy is the standard dose usually administered and will not change.
The study will also assess how the drug is metabolized by the body and changes in tumor
size.
BAY1000394 will be given per mouth, twice a day for three days every week. Treatment will
stop if the tumor continues to grow, if side effects occur which the patient can not
tolerate or if the patients decides to exit treatment.
cisplatin / etoposide or carboplatin / etoposide. Patients with small cell lung cancer will
be treated. Every patient will receive drug treatment, there is no placebo group. Different
groups of patients will receive different dosages of BAY1000394 to determine the safety and
maximum tolerated dose (MTD) of BAY1000394 in combination with chemotherapy. The dose of
chemotherapy is the standard dose usually administered and will not change.
The study will also assess how the drug is metabolized by the body and changes in tumor
size.
BAY1000394 will be given per mouth, twice a day for three days every week. Treatment will
stop if the tumor continues to grow, if side effects occur which the patient can not
tolerate or if the patients decides to exit treatment.
Inclusion Criteria:
- Male or female subjects aged >/=18 years
- Histologically or cytologically confirmed, extensive disease SCLC
- At least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic
resonance imaging (MRI) according to RECIST 1.1. Subjects with non-measurable disease
according to RECIST 1.1 can be included in the Phase Ib part of the study
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
- Life expectancy of at least 12 weeks
- Serum sodium >/=130 mmol/L
Exclusion Criteria:
- Prior systemic anticancer therapy
- Prior radiotherapy (local palliative radiotherapy is permitted)
- History of cardiac disease: congestive heart failure > NYHA Class II, unstable angina
(anginal symptoms at rest), any episodes of angina or history of myocardial
infarction, cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or
digoxin are permitted), previous venous or arterial thrombotic events, pulmonary
embolism
- Moderate or severe hepatic impairment, ie Child-Pugh class B or C
- Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials